Genetesis is a biotechnology and bioinformatics driven company oriented towards personalizing and quantifying characterization and treatment of heart rhythm conditions, like atrial fibrillation, through the use of novel algorithms which analyze, in real-time, the complete human electrophysiology. The EKG has remained unchanged for decades, while it has been 12 years since a single new antiarrhythmic agent has emerged into the market. As a result, there has been a push towards more interventional cardiology, and invasive catheter based mapping of the heart. Genetesis is building electrophysiology platform technology, which extends the applications and diagnostic relevance of the EKG, without compromising its non-invasiveness. Using our proprietary system and methodology, Genetesis quantifies functional heart electrophysiology and proactively profiles a subject’s responsiveness to treatment even before it is administered. Genetesis software therefore enables drug developers or physicians to proactively characterize drug risk profiles, as well as quantify subject responsiveness post-treatment with research grade data.
Posted on: Wed, 08 Oct 2014 02:37:36 +0000
Trending Topics
Recently Viewed Topics
© 2015